Pfizer Inc. (NYSE:PFE) Shares Bought by Edgestream Partners L.P.

Edgestream Partners L.P. lifted its stake in Pfizer Inc. (NYSE:PFE) by 34.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 213,059 shares of the biopharmaceutical company’s stock after purchasing an additional 55,092 shares during the period. Edgestream Partners L.P.’s holdings in Pfizer were worth $6,166,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Olistico Wealth LLC acquired a new stake in shares of Pfizer in the 2nd quarter worth $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer during the second quarter worth about $29,000. Gladius Capital Management LP raised its stake in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP acquired a new position in Pfizer in the 2nd quarter valued at about $31,000. Finally, Financial Connections Group Inc. purchased a new stake in shares of Pfizer in the 2nd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $32.92.

Pfizer Trading Up 1.5 %

Shares of PFE stock opened at $26.21 on Friday. The stock has a market capitalization of $148.53 billion, a P/E ratio of 35.42, a price-to-earnings-growth ratio of 0.70 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a 50 day moving average price of $27.83 and a 200 day moving average price of $28.49.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.41%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.